Whoosh Wellness Review

What Whoosh Wellness charges

• Sermorelin: $199/mo — starting at, per month; a second block on the same page prints $499/mo for the same compound with no stated difference
• NAD+: $199/mo — starting at, per month; a second block on the same page prints $499/mo for the same compound
• Glutathione: $159/mo — starting at, per month
• GHK-Cu: $169/mo — starting at, per month, for the 2% strength; the 4% is $220/mo on the same line
• GHK-Cu: $125 — starting as low as, listed against $166; the product page states no billing period

Two ladders, one page

The pricing page carries a sermorelin block starting at one figure and, further down, a second sermorelin block starting far higher. NAD+ appears twice in the same pattern.

Nothing on the page distinguishes them — not a dose, not a duration, not a plan name. Two prices for one compound, published together, unexplained.

The lower rung is recorded here, with the higher one noted in its qualifier so nobody later treats one as the price.

The testing claim, and what it actually says

The site states that Whoosh protocols are physician-supervised, third-party tested and compounded at licensed US pharmacies, and that every batch is third-party tested for potency and purity before shipment.

Its about page frames that as 'the highest level of testing required by accredited U.S compounding pharmacies' — which describes what the pharmacies are required to do, not something Whoosh does in addition.

No certificate of analysis is published or reachable. The claim is recorded as a claim; the testing is not recorded as documented.

GHK-Cu at two named strengths

The pricing page offers GHK-Cu at two concentrations at two monthly figures, which is more precise than a single copper-peptide price.

A separate product page for a topical GHK-Cu prints a lower figure with no billing period at all, so the same site publishes both a monthly and an unqualified copper-peptide number.

Both are recorded, with their periods as published rather than harmonised.

What is not published

No operating company appears on any page read.

No list of served states appears and no individual pharmacy is named — only the regulatory classes.

Nothing in the live federal warning-letter table attaches to the brand.

How we verified this

• Read the pricing page in full and recorded both sermorelin blocks and both NAD+ blocks rather than only the lower ones.
• Recorded the lower rung as the figure with the higher one stated in its qualifier.
• Read the testing language on the homepage and about page and recorded it as a claim, noting that it describes a pharmacy requirement.
• Recorded the separate topical GHK-Cu product with the period its own page states, which is none.
• Screened the brand against the live federal warning-letter table with a positive and a nonsense control in the same run.